Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017096368) BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING CD19 AND CD3, AND USES THEREOF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/096368 International Application No.: PCT/US2016/064958
Publication Date: 08.06.2017 International Filing Date: 05.12.2016
IPC:
A61K 39/00 (2006.01) ,A61K 39/395 (2006.01) ,C07K 16/00 (2006.01) ,C07K 16/18 (2006.01) ,C07K 16/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
MACROGENICS, INC. [US/US]; 9704 Medical Center Drive Rockville, MD 20850, US
Inventors:
BONVINI, Ezio; US
JOHNSON, Leslie, S.; US
KOENIG, Scott; US
LAM, Chia-Ying, Kao; US
LIU, Liqin; US
MOORE, Paul, A.; US
Agent:
AUERBACH, Jeffrey, I.; US
AUERBACH, Jeffrey, I.; US
Priority Data:
62/263,25704.12.2015US
Title (EN) BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING CD19 AND CD3, AND USES THEREOF
(FR) DIABODIES MONOVALENTS BISPÉCIFIQUES APTES À SE LIER AU CD19 ET AU CD3, ET LEURS UTILISATIONS
Abstract:
(EN) The present invention is directed to a combination therapy involving the administration of: (1) a bi-specific molecule capable of specifically binding to CD19 and to CD3 (i.e., a CD19 x CD3 bi-specific molecule), and (2) a Bruton's Tyrosine Kinase (BTK) inhibitor for the treatment of disease, in particular treatment of a disease associated with or characterized by the expression of CD 19. Preferably, such a CD 19 x CD3 bi-specific molecules are bi-specific monovalent diabodies. The invention is directed to pharmaceutical compositions that contain such a CD19 x CD3 bi-specific molecule, a BTK inhibitor, or a combination of such agents. The invention is additionally directed to methods for the use of such pharmaceutical compositions in the treatment of disease, in particular, treatment of a cancer associated with or characterized by the expression of CD 19.
(FR) La présente invention concerne un traitement combiné comprenant l'administration de : (1) une molécule bispécifique apte à se lier spécifiquement au CD19 et au CD3 (c'est-à-dire une molécule bispécifique CD19 x CD3), et (2) un inhibiteur de la tyrosine kinase de Bruton (BTK), destiné au traitement de maladies, en particulier au traitement de maladies associées à l'expression du CD19 ou caractérisée par l'expression du CD19. De préférence, de telles molécules bispécifiques CD19 x CD3 sont des diabodies monovalents bispécifiques. L'invention concerne des compositions pharmaceutiques qui contiennent une telle molécule bispécifique CD19 x CD3, un inhibiteur de la BTK, ou une combinaison de ces agents. L'invention concerne en outre des méthodes d'utilisation de ces compositions pharmaceutiques dans le traitement de maladies, en particulier dans le traitement de cancers associés à l'expression du CD19, ou caractérisés par l'expression du CD19.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)